Safety and efficacy of colistin compared with imipenem in the treatmentof ventilator-associated pneumonia: a matched case–control study
- 556 Downloads
Our study aimed to determine the efficacy and safety of colistin in the treatment of ventilator-associated pneumonia (VAP) caused by pan-drug-resistant Pseudomonas aeruginosa or Acinetobacter baumanii.
Pairwise, retrospective exposed–unexposed study.
Combined medical and surgical intensive care unit of Habib Bourguiba University Hospital (Sfax, Tunisia).
Sixty patients with VAP caused by pan-drug-resistant A. baumanii or P. aeruginosa matched to 60 controls with VAP caused by A. baumanii or P. aeruginosa susceptible to imipenem. All patients had normal renal function at the onset of antibiotic therapy.
Case patients were treated by colistin intravenously and control patients were treated by imipenem intravenously.
Measurements and results
Baseline characteristics were similar between the colistin and imipenem groups. The mean duration of antibiotic therapy for VAP was 9.5 ± 3.8 days (range 5–22 days) with colistin and 8.9 ± 2.8 days (range 5–20 days) with imipenem (p = 0.32). A favorable clinical response to antibiotic therapy for VAP occurred in 45 patients (75%) in the colistin group and in 43 patients (71.7%) in the imipenem group (p = 0.68). The time to resolution of infectious parameters after the initiation of antibiotic therapy was not statistically different between the two groups. During the antibiotic course, none of the patients in either group developed renal failure.
We conclude that colistin can be a safe and effective option in the treatments of VAP caused by pan-drug-resistant P. aeruginosa or A. baumanii.
KeywordsColistin Ventilator-associated pneumonia Nephrotoxicity Imipenem
- 11.Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, Martin-Lozano D, Prados T, Pachon J (2002) Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumanii meningitis. Eur J Clin Microbiol Infect Dis 21:212–214PubMedCrossRefGoogle Scholar
- 16.Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-WittelI M, Gallego-Lara SL, Madrazo-Osuna J (2003) Treatment of multidrug-resistant Acinetobacter baumanii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36:1111–1118PubMedCrossRefGoogle Scholar
- 23.Marquette CH, Georges H, Wallet F, Ramon P, Saulnier F, Neviere R, Mathieu D, Rime A, Tonnel AB (1993) Diagnostic efficiency of endotracheal aspirates with quantitative bacterial cultures in intubated patients with suspected pneumonia. Comparison with the protected specimen brush. Am Rev Respir Dis 148:138–144PubMedGoogle Scholar
- 25.Anon (2000) Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standards document M7-A5. National Committee for Clinical Laboratory Standards, Wayne, PA, USAGoogle Scholar
- 26.Anon (2000) Performance standard for antimicrobial susceptibility testing. Document M100-S10. National Committee for Clinical Laboratory Standards, Wayne, PA, USAGoogle Scholar